Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
Open Access
Abstract
Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.Keywords
Funding Information
- Science development fund of the Warsaw University of Life Sciences—SGGW and by the MACOV project (101099232)
- European Union’s Horizon 2022 research and innovation program (101099232)
This publication has 232 references indexed in Scilit:
- Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian CancerJAMA Oncology, 2023
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian CancerJAMA Oncology, 2021
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapyJournal of Cellular Biochemistry, 2018
- Incidence and mortality in epithelial ovarian cancer by family history of any cancerCancer, 2011
- Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancerCancer, 2010
- Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinomaCancer, 2006
- Complete Salvage Surgical Cytoreduction Improves Further Survival of Patients with Late Recurrent Ovarian CancerGynecologic Oncology, 2000
- Cross-Resistance, Cisplatin Accumulation, and Platinum–DNA Adduct Formation and Removal in Cisplatin-Sensitive and -Resistant Human Hepatoma Cell LinesExperimental Cell Research, 1996
- Hairy cell leukemia: clinical features and therapeutic advancesCancer and Metastasis Reviews, 1987